By: Sang Hyo Kim, Staff Editor – The Mayo Clinic reported in the American Journal of Gastroenterology that 1.8 million people in the United States suffer from celiac disease.1 More notably, of this population, over 75% of people are unaware that they even have this condition. While other studies have been conducted to determine the…

By: Kevin Lin, PharmD Candidate c/o 2015 – This April, the FDA approved three sublingual immunotherapies for pollen induced allergic rhinitis: Grastek® (Timothy Grass Pollen Allergen Extract), Oralair® (Grass Pollen Allergen Extract), and Ragwitek® (Short Ragweed Pollen Allergen Extract). Formulated by Merck, Grastek® is Timothy grass pollen allergen extract. It is approved for patients ages…

By: Ada Seldin, Staff Editor – The overuse of antipsychotics in the nursing home population for off-label indications continues to impact patient safety. In 2005, the FDA issued a black box warning that stated, “The treatment of behavioral disorders in elderly patients with dementia with atypical antipsychotic medications is associated with increased mortality.” The evidence…

By: Katharine Cimmino, Editor-in-Chief – Pressure ulcers can be a painful condition decreasing the quality of life of patients and prolonging hospital stays.1 About 10% of hospital inpatients and 26% of hospice admissions have pressure sores.2 Pressure ulcers are injuries that occur when pressure is applied for prolonged periods of time over bony prominences.1 There…

By: Caitie Stehling, PharmD Candidate c/o 2015 – St. John’s University is grounded in its Catholic, Vincentian, and Metropolitan mission. Students from all different colleges take pride in being able to give back to society. This year, Phi Lambda Sigma, the Pharmacy Leadership Society (PLS), participated in the Alzheimer’s Walk at Corona Park in Queens.…

By: Jenny Park, PharmD Candidate c/o 2015 – On July 12, 2013, the FDA approved afatinib (GilotrifTM) as a new first-line treatment for patients with late-stage non-small cell lung cancer (NSCLC), a type of carcinoma where specific types of epidermal growth factor receptor (EGFR) gene mutations are expressed.1 The drug afatinib irreversibly blocks EGFR, also…

By: Katharine Cimmino, Editor-in-Chief – Marijuana, also known as “grass,” “pot,” “joint,” “weed,” “reefer,” “hashish,” and “Mary Jane,” is a very popular illicit drug.1 According to the National Survey on Drug Use and Health, “In 2012, 5.4 million persons aged 12 or older used marijuana on a daily or almost daily basis in the past 12…

By: Davidta Brown, Staff Editor – When the seasons transition from winter into spring every year, healthcare providers brace for a shift into a time of increased sneezes, requests for cough medication, and vaccinations, otherwise known as flu season. The rounds of illness that pass each year are usually more of an annoyance than a…

By Sunhae Chang, PharmD Candidate c/o 2013 – When patients complain of heartburn, the blame usually shifts to gastroesophageal reflux disease (GERD).  Therefore, patients receive the “standard therapies for GERD”: antacids, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), or prokinetics.1,2  Luckily, most patients respond well to these agents.1,2  Unfortunately, the not-as-lucky ones, despite PPI…

By: Lunbao (Jerry) Huang, Pharm.D. Candidate c/o 2013 – Donepezil, brand name Aricept®, is an acetylcholinesterase inhibitor indicated as monotherapy for Alzheimer’s disease, the most common form of dementia.  Cholinergic deficiency in the cortex and basal forebrain contributes to cognitive deficits in these patients.  Donepezil reversibly, noncompetitively inhibits centrally active acetylcholinesterase, the enzyme responsible for…

By: Alexandra Alleva, Pharm.D. Candidate c/o 2013 – On February 17, 2012, the US Food and Drug Administration (FDA) approved the first medication indicated specifically for patients with endogenous Cushing’s syndrome, a hormone disorder characterized by elevated blood levels of cortisol.  Mifepristone (Korlym®) is for the treatment of glucose intolerance and Type 2 Diabetes Mellitus…

By: Mohamed Dungersi – On February 28, the U.S. Food and Drug Administration (FDA) approved important safety label changes for the class of cholesterol-lowering drugs known as statins.  Aligned with the FDA’s goal to provide the public with more information for the safe and effective use of statins, the agency made several modifications to the…